A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells

European Journal of Cancer

Volumn 46, Issue 9, 2010, Pages 1668-1678

  Aneja, Ritu ^a   Miyagi, Tohru ^b   Karna, Prasanthi ^a   Ezell, Tucker ^a   Shukla, Deep ^a   Vij Gupta, Meenakshi ^c   Yates, Clayton ^d   Chinni, Sreenivasa R ^e   Zhau, Haiyen ^f   Chung, Leland W K ^f   Joshi, Harish C ^g  

^a GEORGIA STATE UNIVERSITY   (United States)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^c West Georgia Hospital   (United States)

^d TUSKEGEE UNIVERSITY   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Prostate cancer; Tubulin binding

Indexed keywords

(9 BROMO 4 METHOXY 6 METHYL 5,6,7,8 TETRAHYDRO[1,3] DIOXOLO[4,5 G] ISOQUINOLIN 5 YL) 6,7 DIMETHOXYISOBENZOFURAN 1(3H)ONE; ALKALOID DERIVATIVE; CASPASE; EM 011; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; CASPASE 3; EM011 COMPOUND; ISOQUINOLINE DERIVATIVE; TUBULIN MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MALE; MITOSIS SPINDLE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; METABOLISM; MITOCHONDRION; MITOSIS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; DIOXOLES; G2 PHASE; HUMANS; ISOQUINOLINES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOCHONDRIA; MITOSIS; PROSTATIC NEOPLASMS; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952564020     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.017     Document Type: Article

References (48)

1. Williams H., and Powell I.J. Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities. Methods Mol Biol 472 (2009) 439-453
2. Ross L.E., and Uhler R.J. Age, race, and repeated prostate-specific antigen (PSA) test use in the National Health Interview Survey. Ethn Dis 16 (2006) 244-247
3. Loberg R.D., Logothetis C.J., Keller E.T., and Pienta K.J. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 23 (2005) 8232-8241
4. O'Reilly T., McSheehy P.M., Wenger F., et al. Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo. Prostate 65 (2005) 231-240
5. Sava T., Basso U., Porcaro A., and Cetto G.L. New standards in the chemotherapy of metastatic hormone-refractory prostate. Exp Rev Anticancer Ther 5 (2005) 53-62
6. Hsieh C.L., and Chung L.W. New prospectives of prostate cancer gene therapy: molecular targets and animal models. Crit Rev Eukaryot Gene Expr 11 (2001) 77-120
7. Kish J.A., Bukkapatnam R., and Palazzo F. The treatment challenge of hormone-refractory prostate cancer. Cancer Control 8 (2001) 487-495
8. Carroll P.R., Kantoff P.W., Balk S.P., et al. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 60 Suppl (2002) 1
9. Chodak G.W., Keane T., and Klotz L. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 60 (2002) 201
10. Petrylak D.P. Docetaxel for the treatment of hormone-refractory prostate cancer. Rev Urol 5 Suppl 2 (2003) S14-S21
11. Mancuso A., Oudard S., and Sternberg C.N. Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. Crit Rev Oncol Hematol 61 (2007) 176-185
12. Moore C.N., and George D.J. Update in the management of patients with hormone-refractory prostate cancer. Curr Opin Urol 15 (2005) 157-162
13. Rowinsky E.K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48 (1997) 353-374
14. Bhandari M.S., Petrylak D.P., and Hussain M. Clinical trials in metastatic prostate cancer-has there been real progress in the past decade?. Eur J Cancer 41 (2005) 941-953
15. Ye K., Ke Y., Keshava N., et al. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci USA 95 (1998) 1601-1606
16. Zhou J., Gupta K., Aggarwal S., et al. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol Pharmacol 63 (2003) 799-807
17. Aneja R., Zhou J., Zhou B., Chandra R., and Joshi H.C. Treatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in mice. Mol Cancer Ther 5 (2006) 2366-2377
18. Aneja R., Zhou J., Vangapandu S.N., et al. Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. Blood 107 (2006) 2486-2492
19. Aneja R., Vangapandu S.N., Lopus M., et al. Synthesis of microtubule-interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell death. Biochem Pharmacol 72 (2006) 415-426
20. Aneja R., Lopus M., Zhou J., et al. Rational design of the microtubule-targeting anti-breast cancer drug EM015. Cancer Res 66 (2006) 3782-3791
21. Aneja R., Liu M., Yates C., et al. Multidrug resistance-associated protein-overexpressing teniposide-resistant human lymphomas undergo apoptosis by a tubulin-binding agent. Cancer Res 68 (2008) 1495-1503
22. Aneja R., Vangapandu S.N., Lopus M., et al. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. Mol Pharmacol 69 (2006) 1801-1809
23. Zhou J., Liu M., Luthra R., et al. EM012, a microtubule-interfering agent, inhibits the progression of multidrug-resistant human ovarian cancer both in cultured cells and in athymic nude mice. Cancer Chemother Pharmacol 55 (2005) 461-465
24. Karna P., Sharp S.M., Yates C., Prakash S., and Aneja R. EM011 activates a survivin-dependent apoptotic program in human non-small cell lung cancer cells. Mol Cancer 8 (2009) 93
25. Barken I., Geller J., and Rogosnitzky M. Noscapine inhibits human prostate cancer progression and metastasis in a mouse model. Anticancer Res 28 (2008) 3701-3704
26. Mahmoudian M., and Rahimi-Moghaddam P. The anti-cancer activity of noscapine: a review. Recent Pat Anticancer Drug Discov 4 (2009) 92-97
27. Hiser L., Herrington B., and Lobert S. Effect of noscapine and vincristine combination on demyelination and cell proliferation in vitro. Leuk Lymphoma 49 (2008) 1603-1609
28. Heidari N., Goliaei B., Moghaddam P.R., Rahbar-Roshandel N., and Mahmoudian M. Apoptotic pathway induced by noscapine in human myelogenous leukemic cells. Anticancer Drugs 18 (2007) 1139-1147
29. Newcomb E.W., Lukyanov Y., Schnee T., et al. Noscapine inhibits hypoxia-mediated HIF-1alpha expression and angiogenesis in vitro: a novel function for an old drug. Int J Oncol 28 (2006) 1121-1130
30. Jackson T., Chougule M.B., Ichite N., Patlolla R.R., and Singh M. Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol 63 (2008) 117-126
31. Aneja R., Dhiman N., Idnani J., et al. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemother Pharmacol 60 (2007) 831-839
32. Aneja R., Asress S., Dhiman N., et al. Non-toxic melanoma therapy by a novel tubulin-binding agent. Int J Cancer 126 (2010) 256-265
33. Skehan P., Storeng R., Scudiero D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82 (1990) 1107-1112
34. Zhou J, Geng G, Wu JH. Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants. Invest New Drugs 2009;April 24 [Epub ahead of print].
35. Gan L., Chen S., Wang Y., et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 69 (2009) 8386-8394
36. Wu H.C., Hsieh J.T., Gleave M.E., et al. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 57 (1994) 406-412
37. Zhou J., Panda D., Landen J.W., Wilson L., and Joshi H.C. Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. J Biol Chem 277 (2002) 17200-17208
38. Amon A. The spindle checkpoint. Curr Opin Genet Dev 9 (1999) 69-75
39. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 35 (2007) 495-516
40. Fadeel B., and Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med 258 (2005) 479-517
41. Reed J.C. Bcl-2 family proteins. Oncogene 17 25 (1998) 3225-3236
42. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
43. Pathan N., Aime-Sempe C., Kitada S., et al. Microtubule-targeting drugs induce bcl-2 phosphorylation and association with Pin1. Neoplasia 3 (2001) 550-559
44. Yu J., Zhang L., Hwang P.M., Kinzler K.W., and Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7 (2001) 673-682
45. Jiang Q., Wong J., and Ames B.N. Gamma-tocopherol induces apoptosis in androgen-responsive LNCaP prostate cancer cells via caspase-dependent and independent mechanisms. Ann NY Acad Sci 1031 (2004) 399-400
46. Rixe O., and Fojo T. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?. Clin Cancer Res 13 (2007) 7280-7287
47. Hsieh C.L., Xie Z., Liu Z.Y., et al. A luciferase transgenic mouse model: visualization of prostate development and its androgen responsiveness in live animals. J Mol Endocrinol 35 (2005) 293-304
48. Landen J.W., Lang R., McMahon S.J., et al. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res 62 (2002) 4109-4114